Home
/
Decoy Therapeutics Inc.
/
Financials
/
Quarterly
Decoy Therapeutics Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Decoy Therapeutics Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2023
Mar 31, 2023
$0
May 11, 2023
Q3
2022
Sep 30, 2022
$0
Nov 10, 2022
Q2
2022
Jun 30, 2022
$0
Aug 5, 2022
Q1
2023
Mar 31, 2022
$0
May 11, 2023
Q3
2022
Sep 30, 2021
$0
Nov 10, 2022
Q2
2022
Jun 30, 2021
$571.4K
Aug 5, 2022
Q1
2022
Mar 31, 2021
$1.27M
May 12, 2022
Q3
2021
Sep 30, 2020
$1.38M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$1.24M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.13M
May 12, 2021
Q3
2020
Sep 30, 2019
$874.9K
Nov 12, 2020
Q2
2020
Jun 30, 2019
$895.8K
Aug 12, 2020
Q1
2020
Mar 31, 2019
$655.6K
May 15, 2020
Q3
2019
Sep 30, 2018
$469.1K
Nov 12, 2019
Q2
2019
Jun 30, 2018
$245.5K
Jul 17, 2019
Q1
2019
Mar 31, 2018
$178.6K
May 1, 2019
Q3
2018
Sep 30, 2017
$413.6K
Nov 5, 2018
Q2
2018
Jun 30, 2017
$335.5K
Aug 1, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$178.6K
May 2, 2018
Q3
2017
Sep 30, 2017
$413.6K
Nov 6, 2017
Q2
2017
Jun 30, 2017
$335.5K
Aug 2, 2017
Q1
2018
Mar 31, 2017
$242.5K
May 2, 2018
Q3
2017
Sep 30, 2016
$599.1K
Nov 6, 2017
Q2
2017
Jun 30, 2016
$112.7K
Aug 2, 2017
Q1
2017
Mar 31, 2016
$0
May 3, 2017
Q3
2016
Sep 30, 2015
$0
Nov 2, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($873.5K)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($957.8K)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($957.8K)
Nov 14, 2025
Q2
2025
Mar 31, 2025
($1.71M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($1.71M)
May 14, 2025
Q3
2025
Mar 31, 2025
($1.71M)
Nov 14, 2025
Q3
2025
Sep 30, 2024
($972.1K)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.42M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($1.42M)
Nov 14, 2025
Q1
2025
Mar 31, 2024
($1.72M)
May 14, 2025
Q2
2025
Mar 31, 2024
($1.72M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($1.72M)
Nov 14, 2025
Q3
2024
Sep 30, 2023
($2.44M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($3.88M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($3.88M)
Aug 9, 2024
Q2
2024
Mar 31, 2023
($5.34M)
Aug 9, 2024
Q3
2024
Mar 31, 2023
($5.34M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($5.34M)
May 13, 2024
Q3
2023
Sep 30, 2022
($14.41M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($4.72M)
Aug 10, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($895.1K)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($965.6K)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($1.72M)
May 14, 2025
Q3
2025
Sep 30, 2024
($1.01M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.47M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($1.77M)
May 14, 2025
Q3
2024
Sep 30, 2023
($2.53M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($3.97M)
Aug 9, 2024
Q1
2024
Mar 31, 2023
($5.42M)
May 13, 2024
Q3
2023
Sep 30, 2022
($14.49M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($4.76M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($6.12M)
May 11, 2023
Q3
2022
Sep 30, 2021
($3.75M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($3.12M)
Aug 5, 2022
Q1
2022
Mar 31, 2021
($1.80M)
May 12, 2022
Q3
2021
Sep 30, 2020
($1.76M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($1.90M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($2.37M)
May 12, 2021
Q3
2020
Sep 30, 2019
($3.76M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($912.1K)
Aug 12, 2020